Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.
Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Ferrarotto R, et al. Among authors: ahnert jr. Adv Ther. 2021 Aug;38(8):4581-4591. doi: 10.1007/s12325-021-01807-6. Epub 2021 Jul 9. Adv Ther. 2021. PMID: 34241781 Clinical Trial.
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing.
Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Nowlen CJ, et al. Among authors: ahnert jr. J Immunother Precis Oncol. 2024 Feb 5;7(1):7-17. doi: 10.36401/JIPO-23-2. eCollection 2024 Feb. J Immunother Precis Oncol. 2024. PMID: 38327755 Free PMC article.
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.
Ngoi NYL, Tang TY, Gaspar CF, Pavlick DC, Buchold GM, Scholefield EL, Parimi V, Huang RSP, Janovitz T, Danziger N, Levy MA, Pant S, De Armas AD, Kumpula D, Ross JS, Javle M, Rodon Ahnert J. Ngoi NYL, et al. Oncologist. 2024 Jun 3;29(6):493-503. doi: 10.1093/oncolo/oyae011. Oncologist. 2024. PMID: 38330461 Free PMC article.
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Fu S, et al. Among authors: ahnert jr. J Clin Oncol. 2023 Mar 20;41(9):1725-1734. doi: 10.1200/JCO.22.00830. Epub 2022 Dec 5. J Clin Oncol. 2023. PMID: 36469840 Free PMC article. Clinical Trial.
Overview of Ocular Side Effects of Selinexor.
Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Al-Zubidi N, et al. Among authors: ahnert jr. Oncologist. 2021 Jul;26(7):619-623. doi: 10.1002/onco.13756. Epub 2021 Apr 8. Oncologist. 2021. PMID: 33728727 Free PMC article. Review.
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Yao S, et al. Among authors: ahnert jr. Sci Rep. 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. Sci Rep. 2022. PMID: 35610322 Free PMC article. Review.
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Mendoza TR, et al. Among authors: ahnert jr. Sci Rep. 2022 Aug 23;12(1):14367. doi: 10.1038/s41598-022-16588-3. Sci Rep. 2022. PMID: 35999229 Free PMC article. Clinical Trial.
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. Han G, et al. Among authors: ahnert jr. Nat Commun. 2021 Sep 23;12(1):5606. doi: 10.1038/s41467-021-25894-9. Nat Commun. 2021. PMID: 34556668 Free PMC article.
15 results